190 related articles for article (PubMed ID: 37585660)
1. From Thalidomide to Rational Molecular Glue Design for Targeted Protein Degradation.
Oleinikovas V; Gainza P; Ryckmans T; Fasching B; Thomä NH
Annu Rev Pharmacol Toxicol; 2024 Jan; 64():291-312. PubMed ID: 37585660
[TBL] [Abstract][Full Text] [Related]
2. Protein degraders - from thalidomide to new PROTACs.
Ito T
J Biochem; 2024 Apr; 175(5):507-519. PubMed ID: 38140952
[TBL] [Abstract][Full Text] [Related]
3. Exploiting ubiquitin ligase cereblon as a target for small-molecule compounds in medicine and chemical biology.
Ito T; Yamaguchi Y; Handa H
Cell Chem Biol; 2021 Jul; 28(7):987-999. PubMed ID: 34033753
[TBL] [Abstract][Full Text] [Related]
4. Ligand-mediated protein degradation reveals functional conservation among sequence variants of the CUL4-type E3 ligase substrate receptor cereblon.
Akuffo AA; Alontaga AY; Metcalf R; Beatty MS; Becker A; McDaniel JM; Hesterberg RS; Goodheart WE; Gunawan S; Ayaz M; Yang Y; Karim MR; Orobello ME; Daniel K; Guida W; Yoder JA; Rajadhyaksha AM; Schönbrunn E; Lawrence HR; Lawrence NJ; Epling-Burnette PK
J Biol Chem; 2018 Apr; 293(16):6187-6200. PubMed ID: 29449372
[TBL] [Abstract][Full Text] [Related]
5. USP15 antagonizes CRL4
Nguyen TV
Proc Natl Acad Sci U S A; 2021 Oct; 118(40):. PubMed ID: 34583995
[TBL] [Abstract][Full Text] [Related]
6. Discovery of Molecular Glue Degraders via Isogenic Morphological Profiling.
Ng A; Offensperger F; Cisneros JA; Scholes NS; Malik M; Villanti L; Rukavina A; Ferrada E; Hannich JT; Koren A; Kubicek S; Superti-Furga G; Winter GE
ACS Chem Biol; 2023 Dec; 18(12):2464-2473. PubMed ID: 38098458
[TBL] [Abstract][Full Text] [Related]
7. Targeting cereblon in hematologic malignancies.
Fuchs O
Blood Rev; 2023 Jan; 57():100994. PubMed ID: 35933246
[TBL] [Abstract][Full Text] [Related]
8. Ligands for cereblon: 2017-2021 patent overview.
Kazantsev A; Krasavin M
Expert Opin Ther Pat; 2022 Feb; 32(2):171-190. PubMed ID: 34704527
[TBL] [Abstract][Full Text] [Related]
9. E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones.
Ishida T; Ciulli A
SLAS Discov; 2021 Apr; 26(4):484-502. PubMed ID: 33143537
[TBL] [Abstract][Full Text] [Related]
10. Molecular mechanisms of thalidomide and its derivatives.
Ito T; Handa H
Proc Jpn Acad Ser B Phys Biol Sci; 2020; 96(6):189-203. PubMed ID: 32522938
[TBL] [Abstract][Full Text] [Related]
11. Cereblon target validation using a covalent inhibitor of neosubstrate recruitment.
Dann GP; Liu H; Nowak RP; Jones LH
Methods Enzymol; 2023; 681():155-167. PubMed ID: 36764755
[TBL] [Abstract][Full Text] [Related]
12. Chemical approaches to targeted protein degradation through modulation of the ubiquitin-proteasome pathway.
Collins I; Wang H; Caldwell JJ; Chopra R
Biochem J; 2017 Mar; 474(7):1127-1147. PubMed ID: 28298557
[TBL] [Abstract][Full Text] [Related]
13. [Development of novel cereblon modulators and their target molecules].
Ito T
Rinsho Ketsueki; 2022; 63(6):573-579. PubMed ID: 35831190
[TBL] [Abstract][Full Text] [Related]
14. A novel Cereblon E3 ligase modulator with antitumor activity in gastrointestinal cancer.
Lier S; Sellmer A; Orben F; Heinzlmeir S; Krauß L; Schneeweis C; Hassan Z; Schneider C; Patricia Gloria Schäfer A; Pongratz H; Engleitner T; Öllinger R; Kuisl A; Bassermann F; Schlag C; Kong B; Dove S; Kuster B; Rad R; Reichert M; Wirth M; Saur D; Mahboobi S; Schneider G
Bioorg Chem; 2022 Feb; 119():105505. PubMed ID: 34838332
[TBL] [Abstract][Full Text] [Related]
15. Discovery of CRBN as a target of thalidomide: a breakthrough for progress in the development of protein degraders.
Yamamoto J; Ito T; Yamaguchi Y; Handa H
Chem Soc Rev; 2022 Aug; 51(15):6234-6250. PubMed ID: 35796627
[TBL] [Abstract][Full Text] [Related]
16. Profiling CELMoD-Mediated Degradation of Cereblon Neosubstrates.
Thompson JW; Clayton T; Khambatta G; Bateman LA; Carroll CW; Chamberlain PP; Matyskiela ME
Methods Mol Biol; 2021; 2365():283-300. PubMed ID: 34432250
[TBL] [Abstract][Full Text] [Related]
17. Cereblon: promise and challenges for combating human diseases.
Kim HK; Seol JE; Ahn SW; Jeon S; Park CS; Han J
Pflugers Arch; 2021 Nov; 473(11):1695-1711. PubMed ID: 34553266
[TBL] [Abstract][Full Text] [Related]
18. Crbn-based molecular Glues: Breakthroughs and perspectives.
An J; Zhang X
Bioorg Med Chem; 2024 Apr; 104():117683. PubMed ID: 38552596
[TBL] [Abstract][Full Text] [Related]
19. The novel cereblon modulator CC-885 inhibits mitophagy via selective degradation of BNIP3L.
Hao BB; Li XJ; Jia XL; Wang YX; Zhai LH; Li DZ; Liu J; Zhang D; Chen YL; Xu YH; Lee SK; Xu GF; Chen XH; Dang YJ; Liu B; Tan MJ
Acta Pharmacol Sin; 2020 Sep; 41(9):1246-1254. PubMed ID: 32210356
[TBL] [Abstract][Full Text] [Related]
20. Computational investigations of indanedione and indanone derivatives in drug discovery: Indanone derivatives inhibits cereblon, an E3 ubiquitin ligase component.
Nayek U; Basheer Ahamed SI; Mansoor Hussain UH; Unnikrishnan MK; Abdul Salam AA
Comput Biol Chem; 2022 Dec; 101():107776. PubMed ID: 36252444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
